IceCure appoints Meir Peleg CFO as ProSense sales rise post-FDA clearance
IceCure Medical named Meir Peleg CFO effective May 17, leveraging his 20+ years of leadership and prior Nasdaq IPO experience to support rising ProSense sales after FDA clearance for low-risk breast cancer. It will appoint Dr. Richard Fine as Medical Director in Q2 to advance breast cryoablation programs.
1. CFO Appointment
IceCure Medical will install Meir Peleg as CFO effective May 17, 2026, bringing over 20 years of financial leadership, including a Nasdaq IPO and large-scale capital raises, to strengthen the company’s financial infrastructure during its commercial expansion.
2. Medical Leadership & Tech Search
In Q2 2026, IceCure plans to appoint Dr. Richard Fine as Medical Director to lead breast cryoablation initiatives and support the FDA-approved post-marketing ChoICE study, while initiating a search for a new Chief Technology Officer following its VP R&D’s April departure.
3. ProSense Commercial Momentum
ProSense has gained FDA clearance for treating low-risk breast cancer in women 70+, received a recommendation from the American Society of Breast Surgeons, and is experiencing strong U.S. and global uptake as an alternative to surgical removal.